CRITICAL AND URGENT CARE II PANEL

EDITORIAL BOARD LIAISON

Clarence Chant, Pharm.D., FCCP, FCSHP, BCPS
Clinical Pharmacy Specialist
Critical Care/Research, Pharmacy Department
St. Michael’s Hospital
Assistant Professor
Leslie Dan Faculty of Pharmacy
University of Toronto
Toronto, Ontario, Canada

FUNGAL INFECTIONS IN THE INTENSIVE CARE UNIT

Author

Elizabeth S. Dodds Ashley, Pharm.D., MHS, BCPS
Associate Director of Clinical Pharmacy Services
Department of Pharmacy
Instructor of Medicine
School of Medicine and Dentistry
University of Rochester Medical Center
Rochester, New York
Adjunct Assistant Professor
Department of Medicine – Division of Infectious Diseases
Duke University Medical Center
Durham, North Carolina

Reviewers

Katherine Hammond Chessman, Pharm.D., FCCP, BCPS, BCNSP
Professor
Department of Clinical Pharmacy and Outcome Sciences
Pediatric Pharmacy Practice Residency Program Director
South Carolina College of Pharmacy
Medical University of South Carolina Campus
Clinical Pharmacy Specialist
Pediatrics/Pediatric Surgery
MUSC Children’s Hospital
Charleston, South Carolina

Wade H. Flowers, Pharm.D., FASCP, BCPS, CGP
Director of Pharmacy
Bingham Memorial Hospital
Blackfoot, Idaho

Daniel J.G. Thirion, Pharm.D., FCSHP
Clinical Associate Professor
Faculty of Pharmacy
University of Montreal
Pharmacist
Pharmacy Department
McGill University Health Center
Montreal, Québec, Canada

CONTEMPORARY ISSUES AND NOVEL STRATEGIES TO MANAGE INFECTIONS IN THE CRITICALLY ILL

Authors

Steven J. Martin, Pharm.D., FCCP, FCCM, BCPS
(AQ Infectious Diseases)
Professor and Chairman
Department of Pharmacy Practice
The University of Toledo, College of Pharmacy
Toledo, Ohio

Sandy J. Estrada, Pharm.D., BCPS
Infectious Disease Clinical Specialist
Department of Pharmacy
Lee Memorial Health System
Fort Myers, Florida

Reviewers

Mary C. Byrne, Pharm.D., BCPS
Drug Information Specialist
National Institutes of Health
Bethesda, Maryland

Linda Dresser, Pharm.D.
Pharmacotherapy Specialist – Antimicrobial Stewardship
University Health Network
Assistant Professor
Leslie Dan Faculty of Pharmacy
University of Toronto
Toronto, Ontario, Canada

Brian A. Hemstreet, Pharm.D., BCPS
Associate Professor
Director, Pharmaceutical Care Learning Center
Department of Clinical Pharmacy
University of Colorado School of Pharmacy
Aurora, Colorado
UPDATE IN SEVERE SEPSIS AND SEPTIC SHOCK MANAGEMENT

Authors

Scott T. Micek, Pharm.D., FCCP, BCPS
Clinical Pharmacist, Critical Care
Department of Pharmacy
Barnes-Jewish Hospital
St. Louis, Missouri

Garrett E. Schramm, Pharm.D., BCPS
Assistant Professor of Pharmacy
Mayo College of Medicine
Clinical Pharmacist, Critical Care
Hospital Pharmacy Services
Mayo Clinic
Rochester, Minnesota

Reviewers

Judy W.M. Cheng, Pharm.D., MPH, FCCP, BCPS (AQ Cardiology)
Professor of Pharmacy Practice
Department of Pharmacy Practice
Massachusetts College of Pharmacy and Health Sciences
Clinical Pharmacist
Department of Pharmacy
Brigham and Women’s Hospital
Boston, Massachusetts

Tyree H. Kiser, Pharm.D., BCPS
Assistant Professor
Department of Clinical Pharmacy
University of Colorado School of Pharmacy
Aurora, Colorado

The American College of Clinical Pharmacy and the authors thank the following individuals for their careful review of the Book 2, Critical and Urgent Care II chapters:

Dianne M. Brundage, Pharm.D., FCCP, BCPS, BCOP
Oncology Clinical Pharmacy Specialist
Park Nicollet Health Services Methodist Hospital
Minneapolis, Minnesota

Mary C. Gurnee, Pharm.D.
Pharmacist Consultant
Overland Park, Kansas

Mary Lee, Pharm.D., FCCP, BCPS
Vice President and Chief Academic Officer
Pharmacy and Health Sciences Education
Midwestern University
Professor of Pharmacy Practice
Midwestern University
Chicago College of Pharmacy
Downers Grove, Illinois

THROMBOTIC AND BLEEDING DISORDERS IN THE CRITICALLY ILL

Authors

David Williamson, M.Sc., BCPS
Clinical Associate Professor
Faculty of Pharmacy
University of Montreal
Critical Care Pharmacist
Sacre-Coeur Hospital
Montreal, Quebec, Canada

Anne Julie Frenette, M.Sc.
Clinical Assistant Professor
Faculty of Pharmacy
University of Montreal
Critical Care Pharmacist
Sacre-Coeur Hospital
Montreal, Quebec, Canada
Disclosure of Potential Conflicts of Interest

Consultancies: Elizabeth Dodds Ashley (Shering-Plough, Merck, Pfizer); Danielle Blais (Facts-Care, The Medicines Company); Robert J. DiDomenico (Scios, The Medicines Company, Sanofi-Aventis, Merck, ARCA Biopharma); Ronald A. Floyd (California Society of Health-System Pharmacists); Anne Julie Frenette (Baxter, Merck Frosst, Eli Lilly); Krystal K. Haase (Pharmacology Weekly); Brian A. Hemstreet (Conexus Health); Lisa C. Hutchison (Arkansas Medicaid); Judith Jacobi (Society of Critical Care Medicine, American Board of Applied Toxicology, American Association of Poison Control Centers [spouse or significant other]); Sandra L. Kane-Gill (Baxter, Hospira, Cannon Pharmaceuticals); Steven J. Martin (The Medicines Company, Astellas); Steven Pass (The Medicines Company); John Papadopoulous (Wyeth); Michelle Richardson (Amgen, QualityMetric); Marisel Segarra-Newnham (Tibotec Therapeutics, USP, Annals of Pharmacotherapy); Jeffrey T. Sherer (Sturge-Weber Foundation); Daniel J.G. Thirion (Wyeth, Schering-Plough, Boehringer-Ingelheim [spouse or significant other]); David Williamson (Boehringer-Ingelheim)

Stock Ownership: Katherine H. Chessman (Procter & Gamble [stock owned by spouse or significant other]); Ronald A. Floyd (Eli Lilly, Johnson & Johnson, Pfizer); Lisa C. Hutchison (Cardinal Health); Julie J. Kelsey (Pfizer)

Royalties: Lisa C. Hutchison (ASHP); Judith Jacobi (Fougera [spouse or significant other]);

Grants: Elizabeth Dodds Ashley (Astellas, Schering-Plough [two grants]); Michael L. Bentley (Carilion Clinic, Hospira); Danielle Blais (ASHP); Judy W.M. Cheng (St. Jude's Medical Research Center); Robert J. DiDomenico (Johnson & Johnson, AHRQ, ACCP Research Institute); Linda Dresser (Palumed [two grants]); Anne Julie Frenette (Aventis Pharma); Brian A. Hemstreet (AstraZeneca); Anne L. Hume (AHRQ [two grants], HRSA); Lisa C. Hutchison (Boehringer-Ingelheim, National Institutes of Health); Judith Jacobi (Luminous Medical, Amgen); Sandra L. Kane-Gill (Ortho McNeil); Scott T. Micek (Astellas Pharma, Ortho-McNeil-Janssen, Xcenda); Asad Patanwala (ASHP Foundation); Michelle Richardson (NIH NIDDK [two grants]); Christine M. Stork (Glaxo); Daniel J.G. Thirion (Wyeth Canada, Pfizer Canada)

Honoraria: Elizabeth Dodds Ashley (Merck, Schering-Plough); Danielle Blais (Bayer, Pfizer); Robert J. DiDomenico (Bristol-Myers Squibb, Sanif Pharmaceuticals, Sanofi-Aventis U.S., ACCP, APhA); Sandy J. Estrada (AdvanD, Biomeuneux); Steven J. Martin (Ortho-McNeil – PriCara); Scott T. Micek (Merck, Pfizer); Steven Pass (Pfizer); John Papadopoulous (Wyeth, Boehringer-Ingelheim); Michelle Richardson (Amgen); Daniel J.G. Thirion (Wyeth, Merck Frosst); David Williamson (Boehringer-Ingelheim)

Other:


ROLE OF ACCP: ACCP developed the petition seeking recognition of Pharmacotherapy as a specialty of pharmacy and presented it to the Board of Pharmaceutical Specialties (BPS). As part of its mission to provide leadership, education, advocacy, and resources enabling clinical pharmacists to achieve excellence in practice and research, ACCP also helps pharmacotherapy specialists maintain their certification through PSAP. ACCP reports successful completion of PSAP examinations to BPS for recertification credit. Neither ACCP nor its agents, including the PSAP Editorial Board, authors, reviewers, or other staff, has knowledge of specific examination content, areas of emphasis, or any other information that would compromise the integrity of the examination process.

ROLE OF BPS: The Board of Pharmaceutical Specialties is an autonomous certification agency of the American Pharmacists Association. BPS is totally separate and distinct from ACCP. The Board, through its specialty councils, is responsible for specialty examination content, administration, scoring, and all other aspects of its certification programs. PSAP has been approved by BPS for use in BCPS recertification. Information about the BPS recertification process is available at www.bpsweb.org/recertification/general.cfm. Other questions regarding recertification should be directed to:

Board of Pharmaceutical Specialties
2215 Constitution Avenue  N.W.
Washington, DC 20037
(202) 429-7591
www.bpsweb.org